par Cosmo Pharmaceuticals N.V. (isin : NL0011832936)
Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023
Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results
Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023
16.03.2023 / 06:00 GMT/BST
Dublin, Ireland – 16 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its full-year 2022 results on Thursday, 23 March 2023 at 07:00 am CET.
Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast which will follow at 2:00 pm CET with Mauro Ajani, Founder and Chairman, Alessandro Della Chà, CEO, and Niall Donnelly, CFO, to discuss the 2022 financial and operating results as well as the next milestones of the company.
Live conference call and video webcast presentation:
Date: Thursday, 23 March 2023
Time: 2:00 pm CET
Webcast link: Chrome (recommended) or Firefox https://media.choruscall.eu/mediaframe/webcast.html?webcastid=L3HNXtf4
Please note that there is a function to type in your questions via webcast.
Via phone:
Participants wishing to ask verbal questions via phone, may call the following numbers below. To ensure prompt access, please call approximately ten minutes prior to the scheduled start of the call.
Switzerland / Europe
+41 (0) 58 310 50 00
United Kingdom
+44 (0) 207 107 06 13
United States
+1 (1) 631 570 56 13
The presentation and media release as well as the Annual Report 2022 will be available for download as of 07:00 am CET on 23 March 2023 at www.cosmopharma.com
Replay
The webcast, along with the presentation, will be available online shortly after the event and accessible for three months.
Contact:
Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
End of Media Release
Language: | English |
Company: | Cosmo Pharmaceuticals N.V. |
Riverside 2, Sir John Rogerson’s | |
Dublin 2 Dublin | |
Ireland | |
Phone: | + 353 1 817 0370 |
E-mail: | info@cosmopharma.com |
Internet: | https://www.cosmopharma.com/ |
ISIN: | NL0011832936 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1583775 |
End of News | EQS News Service |
1583775 16.03.2023 GMT/BST